NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from PeptiSlim? Mail in a sample (US only) and let us test it.

Test my supply
74%
Finnrick rating
#241 of 500 ranked vendors
63 of 75 classifiable tests passed
methodology · Purity focus
Finnrick analysis

PeptiSlim's purity-focus record is strongest on Tirzepatide, Retatrutide, and GHK-Cu, where later multi-lab results mostly clear despite earlier identity, purity, and fill misses. Weakness is concentrated in Tesamorelin and sparse Cagrilintide, with Semaglutide marked by an earlier underfill; evidence is recent but batch IDs are uneven.

methodology →
vendor intelligence report
Vendor Intelligence Report: PeptiSlim

Corporate and web-infrastructure records point to a China/Hong Kong PeptiSlim cluster with unresolved ownership and a linked Lilipetide surface. The report also traces an AU/BioSynteq COA system whose independent-lab claim fails file and origin checks.

43 pages8 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$0.64
89%
32
2
GHK-Cu
-
86%
7
3
Retatrutide
$1.00
86%
26
4
Semaglutide
$0.64
69%
4
5
Cagrilintide
$1.53
54%
2
6
Tesamorelin
$2.30
45%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%18 Feb 2026: 69%18 Feb 2026: 69%18 Feb 2026: 68%19 Feb 2026: 68%20 Feb 2026: 68%20 Feb 2026: 68%22 Feb 2026: 68%26 Feb 2026: 68%26 Feb 2026: 68%3 Mar 2026: 69%4 Mar 2026: 68%4 Mar 2026: 68%6 Mar 2026: 68%7 Mar 2026: 69%7 Mar 2026: 69%10 Mar 2026: 69%16 Mar 2026: 69%25 Mar 2026: 70%25 Mar 2026: 70%23 Apr 2026: 70%12 Jun 2026: 70%12 Jun 2026: 70%17 Jun 2026: 71%17 Jun 2026: 71%17 Jun 2026: 71%17 Jun 2026: 71%22 Jun 2026: 71%23 Jun 2026: 72%26 Jun 2026: 72%26 Jun 2026: 72%26 Jun 2026: 72%26 Jun 2026: 72%26 Jun 2026: 73%14 Jul 2026: 74%21 Jul 2026: 74%21 Jul 2026: 74%28 Aug 2026: 74%28 Aug 2026: 75%5 Sep 2026: 75%29 Oct 2026: 74%17 Nov 2026: current 74%69%70%74%Feb 26Nov 26
Peptide testing

Ordered peptides from PeptiSlim? Mail in a sample (US only) and let us test it.

Test my supply
PeptiSlim test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
29 Oct 2026
Pass
GHK-Cu
lab nameView COA
5 Sep 2026
Pass
Tirzepatide
lab nameView COA
28 Aug 2026
Pass
Tirzepatide
lab nameView COA
28 Aug 2026
Pass
Tirzepatide
lab nameView COA
21 Jul 2026
Pass
Tirzepatide
lab nameView COA
21 Jul 2026
Pass
Tirzepatide
lab nameView COA
14 Jul 2026
Fail
Tesamorelin
lab nameView COA
26 Jun 2026
Pass
Tirzepatide
lab nameView COA
26 Jun 2026
Pass
Tirzepatide
lab nameView COA
26 Jun 2026
Pass
Tirzepatide
lab nameView COA
1-10 of 75

About PeptiSlim test results from Finnrick

PeptiSlim is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 6 peptides and 75 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible PeptiSlim peptides in this dataset are Tirzepatide (32 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 75 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from PeptiSlim? Mail in a sample (US only) and let us test it.

Test my supply